Comprehensive Review of COVID-19: Impacts, Comorbidity, and Management

In late 2019, SARS-CoV-2 sparked the global COVID-19 pandemic. Despite intense research, many aspects of the virus remain puzzling. Rare disease patients, carers, and researchers faced challenges during this period. Elderly and pre-existing conditions exacerbated outcomes, with diabetes, hypertension, and respiratory issues posing risks. Vaccine hesitancy, healthcare disparities, and limited support further complicated matters. Concurrent outbreaks like monkeypox and acute hepatitis disrupted treatment. Disruptions in medical research delayed care, impacting patients. This study sheds light on pandemic disruptions, especially for rare diseases. Procedures were postponed and telemedicine surged, yet crucial therapies were scarce. Diagnostics, treatments, and urgent visits were curtailed. Black fungus co-infections strained resources. Despite related microorganisms, standardized therapies were lacking. Managing SARS-CoV-2 requires understanding its evolving behavior. The pandemic underscored the importance of comprehending viral infections, their impact on vulnerability, and managing medical issues during outbreaks. Co-infections, comorbidities, and hyperlipidemia influenced COVID-19 outcomes. Improving disease management, infection control, and healthcare access is crucial. Rare diseases led to delayed procedures, restricted diagnoses, and therapies. Telemedicine helped, but access to key treatments was limited. Post-pandemic solutions must prioritize patient care and ongoing research.